SEC Comment Letter 0000000000-24-008615 to Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp.
Date: July 29, 2024 · CIK: 0001533040 · Accession: 0000000000-24-008615
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281052
Letter
July 29, 2024 Robert J. Bitterman President and Chief Executive Officer Phio Pharmaceuticals Corp. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, Massachusetts 01752 Re:Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed July 26, 2024 File No. 333-281052 Dear Robert J. Bitterman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Steven J. Abrams, Esq.
Show Raw Text
July 29, 2024
Robert J. Bitterman
President and Chief Executive Officer
Phio Pharmaceuticals Corp.
11 Apex Drive, Suite 300A, PMB 2006
Marlborough, Massachusetts 01752
Re:Phio Pharmaceuticals Corp.
Registration Statement on Form S-1
Filed July 26, 2024
File No. 333-281052
Dear Robert J. Bitterman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Steven J. Abrams, Esq.